肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

PLoS Biology:研究发现转录因子可导致乳腺癌对抗雌激素治疗无应答

2013-01-07 PLoS Biology dxy zhihui_li

转录因子雌激素乳腺癌
关注

　　澳大利亚的科学家们已经证实一种“转录因子”如何引起乳腺癌进展为侵袭性亚型，而且这种亚型缺乏对雌激素的敏感性，同时对于像他莫昔芬和芳香酶抑制剂这样的抗雌激素药物治疗无效。 　　转录因子是一类可以转换基因的“开”或“关”的分子。在这种情况下，所熟知的转录因子“ELF5”在乳腺癌细胞的极早期抑制其对雌激素的敏感性。2008年，来自悉尼Garvan医学研究所的副教授Chris Orma


　　澳大利亚的科学家们已经证实一种“转录因子”如何引起乳腺癌进展为侵袭性亚型，而且这种亚型缺乏对雌激素的敏感性，同时对于像他莫昔芬和芳香酶抑制剂这样的抗雌激素药物治疗无效。

　　转录因子是一类可以转换基因的“开”或“关”的分子。在这种情况下，所熟知的转录因子“ELF5”在乳腺癌细胞的极早期抑制其对雌激素的敏感性。2008年，来自悉尼Garvan医学研究所的副教授Chris Ormandy证实ELF5负责刺激生成乳腺内雌激素受体阴性的细胞，可以在妊娠期间产生乳汁。

　　Ormandy在当前的研究中，与Maria Kalyga博士和David Gallego-Ortega博士一道证实，同样的分子决定了乳腺癌的发生，并且ELF5可以将现发生的肿瘤改变为雌激素不敏感型。研究小组已经描述了ELF5通过怎样的遗传机制来对抗雌激素的作用，同时也证实通过操纵ELF5水平来改变乳腺癌亚型是有可能的。研究结果现已在线发表于具有很大影响力的杂志—PLoS Biology上。

　　Ormandy说：“这项工作告诉我们，癌症之所以会变成抗雌激素难治性，就是因为它们经常借助抬高ELF5水平，从而变为功能性的雌激素受体阴性。这就引出了一个新的治疗选择，即通过操纵ELF5水平来治疗乳腺癌。由于ELF5是胞内的，使用可以靶向产生蛋白质-蛋白质相互作用的小分子或许可以达到目的，或者使用小的抑制性RNAs。同时，通过检测肿瘤内ELF5的含量水平来预测对治疗的反应，并因此指导治疗选择也是可能的。这里我们关键的发现就是借助简单地操纵一种转录因子，我们可以改变乳腺癌的亚型。”



ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer
Abstract
We have previously shown that during pregnancy the E-twenty-six (ETS) transcription factor ELF5 directs the differentiation of mammary progenitor cells toward the estrogen receptor (ER)-negative and milk producing cell lineage, raising the possibility that ELF5 may suppress the estrogen sensitivity of breast cancers. To test this we constructed inducible models of ELF5 expression in ER positive luminal breast cancer cells and interrogated them using transcript profiling and chromatin immunoprecipitation of DNA followed by DNA sequencing (ChIP-Seq). ELF5 suppressed ER and FOXA1 expression and broadly suppressed ER-driven patterns of gene expression including sets of genes distinguishing the luminal molecular subtype. Direct transcriptional targets of ELF5, which included FOXA1, EGFR, and MYC, accurately classified a large cohort of breast cancers into their intrinsic molecular subtypes, predicted ER status with high precision, and defined groups with differential prognosis. Knockdown of ELF5 in basal breast cancer cell lines suppressed basal patterns of gene expression and produced a shift in molecular subtype toward the claudin-low and normal-like groups. Luminal breast cancer cells that acquired resistance to the antiestrogen Tamoxifen showed greatly elevated levels of ELF5 and its transcriptional signature, and became dependent on ELF5 for proliferation, compared to the parental cells. Thus ELF5 provides a key transcriptional determinant of breast cancer molecular subtype by suppression of estrogen sensitivity in luminal breast cancer cells and promotion of basal characteristics in basal breast cancer cells, an action that may be utilised to acquire antiestrogen resistance.    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916938, encodeId=1eba191693821, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jan 26 21:26:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752984, encodeId=a0491e52984db, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Jun 10 19:26:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766815, encodeId=b08b1e6681581, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Dec 14 03:26:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758727, encodeId=35431e5872721, content=<a href='/topic/show?id=1a675894241' target=_blank style='color:#2F92EE;'>#无应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58942, encryptionId=1a675894241, topicName=无应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71ca37362043, createdName=12498717m78(暂无昵称), createdTime=Tue Sep 24 15:26:00 CST 2013, time=2013-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747169, encodeId=d02d1e4716994, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 05 01:26:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818986, encodeId=6103181898631, content=<a href='/topic/show?id=219e98e7065' target=_blank style='color:#2F92EE;'>#雌激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98770, encryptionId=219e98e7065, topicName=雌激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Dec 22 21:26:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307325, encodeId=e3f1130e325de, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537445, encodeId=31eb153e4459d, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-01-26 sunylz

    #Bio#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1916938, encodeId=1eba191693821, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jan 26 21:26:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752984, encodeId=a0491e52984db, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Jun 10 19:26:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766815, encodeId=b08b1e6681581, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Dec 14 03:26:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758727, encodeId=35431e5872721, content=<a href='/topic/show?id=1a675894241' target=_blank style='color:#2F92EE;'>#无应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58942, encryptionId=1a675894241, topicName=无应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71ca37362043, createdName=12498717m78(暂无昵称), createdTime=Tue Sep 24 15:26:00 CST 2013, time=2013-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747169, encodeId=d02d1e4716994, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 05 01:26:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818986, encodeId=6103181898631, content=<a href='/topic/show?id=219e98e7065' target=_blank style='color:#2F92EE;'>#雌激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98770, encryptionId=219e98e7065, topicName=雌激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Dec 22 21:26:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307325, encodeId=e3f1130e325de, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537445, encodeId=31eb153e4459d, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-06-10 hanhaisha2020

    #研究发现#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1916938, encodeId=1eba191693821, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jan 26 21:26:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752984, encodeId=a0491e52984db, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Jun 10 19:26:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766815, encodeId=b08b1e6681581, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Dec 14 03:26:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758727, encodeId=35431e5872721, content=<a href='/topic/show?id=1a675894241' target=_blank style='color:#2F92EE;'>#无应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58942, encryptionId=1a675894241, topicName=无应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71ca37362043, createdName=12498717m78(暂无昵称), createdTime=Tue Sep 24 15:26:00 CST 2013, time=2013-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747169, encodeId=d02d1e4716994, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 05 01:26:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818986, encodeId=6103181898631, content=<a href='/topic/show?id=219e98e7065' target=_blank style='color:#2F92EE;'>#雌激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98770, encryptionId=219e98e7065, topicName=雌激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Dec 22 21:26:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307325, encodeId=e3f1130e325de, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537445, encodeId=31eb153e4459d, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-12-14 12498ebem31暂无昵称

    #Biol#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1916938, encodeId=1eba191693821, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jan 26 21:26:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752984, encodeId=a0491e52984db, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Jun 10 19:26:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766815, encodeId=b08b1e6681581, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Dec 14 03:26:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758727, encodeId=35431e5872721, content=<a href='/topic/show?id=1a675894241' target=_blank style='color:#2F92EE;'>#无应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58942, encryptionId=1a675894241, topicName=无应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71ca37362043, createdName=12498717m78(暂无昵称), createdTime=Tue Sep 24 15:26:00 CST 2013, time=2013-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747169, encodeId=d02d1e4716994, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 05 01:26:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818986, encodeId=6103181898631, content=<a href='/topic/show?id=219e98e7065' target=_blank style='color:#2F92EE;'>#雌激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98770, encryptionId=219e98e7065, topicName=雌激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Dec 22 21:26:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307325, encodeId=e3f1130e325de, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537445, encodeId=31eb153e4459d, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-09-24 12498717m78(暂无昵称)

    #无应答#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1916938, encodeId=1eba191693821, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jan 26 21:26:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752984, encodeId=a0491e52984db, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Jun 10 19:26:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766815, encodeId=b08b1e6681581, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Dec 14 03:26:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758727, encodeId=35431e5872721, content=<a href='/topic/show?id=1a675894241' target=_blank style='color:#2F92EE;'>#无应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58942, encryptionId=1a675894241, topicName=无应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71ca37362043, createdName=12498717m78(暂无昵称), createdTime=Tue Sep 24 15:26:00 CST 2013, time=2013-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747169, encodeId=d02d1e4716994, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 05 01:26:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818986, encodeId=6103181898631, content=<a href='/topic/show?id=219e98e7065' target=_blank style='color:#2F92EE;'>#雌激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98770, encryptionId=219e98e7065, topicName=雌激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Dec 22 21:26:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307325, encodeId=e3f1130e325de, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537445, encodeId=31eb153e4459d, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-09-05 mjldent

    #转录#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1916938, encodeId=1eba191693821, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jan 26 21:26:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752984, encodeId=a0491e52984db, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Jun 10 19:26:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766815, encodeId=b08b1e6681581, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Dec 14 03:26:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758727, encodeId=35431e5872721, content=<a href='/topic/show?id=1a675894241' target=_blank style='color:#2F92EE;'>#无应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58942, encryptionId=1a675894241, topicName=无应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71ca37362043, createdName=12498717m78(暂无昵称), createdTime=Tue Sep 24 15:26:00 CST 2013, time=2013-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747169, encodeId=d02d1e4716994, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 05 01:26:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818986, encodeId=6103181898631, content=<a href='/topic/show?id=219e98e7065' target=_blank style='color:#2F92EE;'>#雌激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98770, encryptionId=219e98e7065, topicName=雌激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Dec 22 21:26:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307325, encodeId=e3f1130e325de, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537445, encodeId=31eb153e4459d, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-12-22 anminleiryan

    #雌激素治疗#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1916938, encodeId=1eba191693821, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jan 26 21:26:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752984, encodeId=a0491e52984db, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Jun 10 19:26:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766815, encodeId=b08b1e6681581, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Dec 14 03:26:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758727, encodeId=35431e5872721, content=<a href='/topic/show?id=1a675894241' target=_blank style='color:#2F92EE;'>#无应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58942, encryptionId=1a675894241, topicName=无应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71ca37362043, createdName=12498717m78(暂无昵称), createdTime=Tue Sep 24 15:26:00 CST 2013, time=2013-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747169, encodeId=d02d1e4716994, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 05 01:26:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818986, encodeId=6103181898631, content=<a href='/topic/show?id=219e98e7065' target=_blank style='color:#2F92EE;'>#雌激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98770, encryptionId=219e98e7065, topicName=雌激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Dec 22 21:26:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307325, encodeId=e3f1130e325de, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537445, encodeId=31eb153e4459d, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-01-09 aliceclz

    #激素治疗#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1916938, encodeId=1eba191693821, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jan 26 21:26:00 CST 2013, time=2013-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752984, encodeId=a0491e52984db, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Mon Jun 10 19:26:00 CST 2013, time=2013-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766815, encodeId=b08b1e6681581, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sat Dec 14 03:26:00 CST 2013, time=2013-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758727, encodeId=35431e5872721, content=<a href='/topic/show?id=1a675894241' target=_blank style='color:#2F92EE;'>#无应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58942, encryptionId=1a675894241, topicName=无应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=71ca37362043, createdName=12498717m78(暂无昵称), createdTime=Tue Sep 24 15:26:00 CST 2013, time=2013-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747169, encodeId=d02d1e4716994, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Thu Sep 05 01:26:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818986, encodeId=6103181898631, content=<a href='/topic/show?id=219e98e7065' target=_blank style='color:#2F92EE;'>#雌激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98770, encryptionId=219e98e7065, topicName=雌激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Dec 22 21:26:00 CST 2013, time=2013-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307325, encodeId=e3f1130e325de, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537445, encodeId=31eb153e4459d, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 09 01:26:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-01-09 lanyan20020090

    #转录因子#

    0

相关资讯

PLoS ONE：转录因子c-Jun保护肝免受β-连环蛋白损伤

Wnt/β-catenin信号通路在肝功能的正常至关重要，而在肝细胞癌（HCC）中，这条信号通路进场是失调的。因此，分析β-catenin活化的早期表型和分子事件对更好地了解肝癌发病是非常有必要的。 AP-1转录因子c-Jun是一个假定的β-catenin靶基因，它能促进肝细胞的存、增殖以及肝癌的发生，这表明c-Jun可能是β-catenin在肝脏中的主要作用靶蛋白。为了解决这个问题，近日研究人

Nat. Immunol：转录因子Lyl-1在产生早期T细胞系祖细胞中发挥关键性作用

T细胞是在胸腺中产生的一类非常重要的细胞，能够协调机体对癌症或感染产生的免疫反应。在一项最新研究中，来自美国贝勒医学院的研究人员领导的一个研究小组发现转录因子Lyl-1是产生能够变成T细胞的最早的细胞所必需的。相关研究结果于2012年7月8日在线发表在Nature Immunology期刊上。 论文通讯作者、贝勒医学院干细胞与再生医学中心主任Margaret Goodell说，这些最早的祖细胞(